STAB (Statera BioPharma) Cash-to-Debt: 0.07 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Cash-to-Debt?

Statera BioPharma STAB Cash-to-Debt is 0.07 as of Sep. 2022.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Statera BioPharma's cash to debt ratio for the quarter that ended in Sep. 2022 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Statera BioPharma couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for Statera BioPharma's Cash-to-Debt or its related term are showing as below:

STAB's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 7.175
* Ranked among companies with meaningful Cash-to-Debt only.

Statera BioPharma  (OTCPK:STAB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Statera BioPharma Cash-to-Debt Related Terms

Statera BioPharma Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Statera BioPharma Cash-to-Debt Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Cash-to-Debt
0.00 0.30 0.12

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.57 0.12 0.05 0.10 0.07

STAB vs NRBO, PALI, BLCM: Cash-to-Debt Comparison

For the Biotechnology subindustry, Statera BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma Cash-to-Debt vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Cash-to-Debt falls into.


Statera BioPharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Statera BioPharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=1.979 / (4.83 + 11.431)
=0.12

Statera BioPharma's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.506 / (6.72 + 0.686)
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.07 mean?
Statera BioPharma (STAB) has a Cash-to-Debt of 0.07 as of Sep. 2022.
Is Statera BioPharma's Cash-to-Debt too high?
Statera BioPharma's current Cash-to-Debt is 0.07. The Biotechnology industry median Cash-to-Debt is 7.18. Statera BioPharma's value of 0.07 is 99% below this industry median.
How does Statera BioPharma's Cash-to-Debt compare to NRBO and PALI?
Statera BioPharma's Cash-to-Debt of 0.07 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 7.18. Statera BioPharma's value of 0.07 is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.18, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Statera BioPharma's current Cash-to-Debt of 0.07 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Statera BioPharma's current Cash-to-Debt is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current Cash-to-Debt of 0.07. The current Cash-to-Debt is 0.07 and 99% below the Biotechnology industry median of 7.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Statera BioPharma (STAB), the current Cash-to-Debt is 0.07 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.